Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|June 28, 2023

DIA 2023: PALADIN Brings Patient Advocacy and Industry Together

New pre-competitive, disease-agnostic Consortium hopes to optimize advocacy group-industry collaboration to ultimately accelerate the pace of medicines development.

In this interview, Vicky DiBiaso, Global Head, Patient Informed Development & Health Value Translation at Sanofi and Kenneth Getz, Executive Director/Professor, Tufts CSDD and Founder/Board Chair, CISCRP, discuss the formation, mission and goals for the newly-launched Patient Advocacy Leaders And Drug (Development) Industry Network or PALADIN.

Read more on PALADIN's formation.


Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.